Azitra Inc Profile last edited on: 6/6/2024
CAGE: 74XA8
UEI: L26KNREPFJQ9
Business Identifier: Microbiome-based therapeutics to treat serious skin diseases Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 03
County: New Haven
Congr. District: 03
County: New Haven
Public Profile
Founded by scientists out of Yale University working with other scientists in dermatology, microbiology, and genetic engineering, Azitra is organized around advancing its programs in atopic dermatitis and targeted orphan indications. The focus is on bringing microbiome-based therapeutics to the treatment of skin diseases. Azitras proprietary candidate, "AZT-01," is a recombinant strain of a safe, commensal skin bacterium that secretes therapeutic proteins for the treatment of skin disease. At the intersection of the fields of microbiomics, synthetic biology, and protein engineering Azitra is developing a microbiome based platform to deliver innovative, inexpensive, and sustainable treatments for skin disease and conditions ranging from atopic dermatitis to MRSA skin infections using our novel bacterial platform engineered to secrete therapeutic proteins.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
10-14Revenue Range
1.5M-2MVC funded?
YesPublic/Private
Publicly TradedStock Info
NYSE : AZTRIP Holdings
15-19Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2019 | 2 | NSF | $944,727 | |
Project Title: Re-engineered skin bacteria as a novel topical drug delivery system | ||||
2018 | 1 | NIH | $225,000 | |
Project Title: Bioengineered Skin Microbiota for Cutaneous Mitigation of Netherton Syndrome | ||||
2016 | 1 | NIH | $150,000 | |
Project Title: Topical Application of Heterologous Protein-Expressing Staphylococcus Epidermidis for Potential Therapeutic Treatment of Skin Diseases |
Key People / Management
Richard Andrews -- President and Chief Executive Officer
Francisco Salva -- President and CEO
David Dodds -- Chief Technical Officer
Leonard M Milstone
Azim Munivar -- former CEO and Co-Founder
Julia Oh -- Co-Principal Investigator
Mark Sampson -- Chief Scientific Officer
Norman Staskey -- Chief Financial Officer
Travis M Whitfill -- Co-Founder Chief Science Officer
Francisco Salva -- President and CEO
David Dodds -- Chief Technical Officer
Leonard M Milstone
Azim Munivar -- former CEO and Co-Founder
Julia Oh -- Co-Principal Investigator
Mark Sampson -- Chief Scientific Officer
Norman Staskey -- Chief Financial Officer
Travis M Whitfill -- Co-Founder Chief Science Officer